Navigation Links
Biodel Inc. to Present at the BioCentury Future Leaders Conference on March 27th, 2008
Date:3/20/2008

DANBURY, Conn., March 20 /PRNewswire-FirstCall/ -- Biodel Inc. (Nasdaq: BIOD) today announced that Gerard Michel, Chief Financial Officer, Vice President of Corporate Development and Treasurer of Biodel, will present a corporate update at the BioCentury Future Leaders Conference on Thursday, March 27, 2008 at 3:00 p.m. Eastern Time. The conference will be held at the Millennium Broadway Hotel and Conference Center in New York City.

Interested parties may access a link to a live webcast of the corporate presentation in the investor relations section of Biodel's website at http://www.biodel.com. An archive of the presentation will be available at the same location.

About Biodel Inc.

Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for endocrine disorders, such as diabetes and osteoporosis. Biodel's product candidates are developed by using VIAdel(TM) technology, which reformulates existing FDA- approved peptide drugs. The Company's lead product candidate, VIAject(TM), is an ultra rapid-acting injectable meal-time insulin in development for use by patients with Type 1 or Type 2 diabetes. VIAject(TM) is currently being tested in two pivotal Phase III clinical trials. Biodel's pipeline also includes VIAtab(TM), a sublingual tablet formulation of insulin in the Phase I stage of clinical testing, and two pre-clinical osteoporosis product candidates. For further information regarding Biodel, please visit the Company's website at http://www.biodel.com.

BIOD-G


'/>"/>
SOURCE Biodel Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Biodel Inc. Reports First Quarter Fiscal Year 2008 Financial Results
2. Biodel Inc. to Announce First Quarter Fiscal Year 2008 Financial Results on February 14, 2008
3. Biodel Inc. Announces Pricing of Public Offering
4. Biodel to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on December 11, 2007
5. Brian J.G. Pereira, M.D. Joins Biodels Board of Directors
6. Biodel Inc. to Present at Natixis Bleichroeder Hidden Gems Conference on October 8, 2007
7. Biodel Inc. to Present at BIO InvestorForum 2007 Conference on October 11, 2007
8. Biodel to Amend June 30, 2007 10-Q to Correct Non-Cash Share-Based Compensation Expense
9. Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting
10. Ralf Rosskamp, M.D. Joins Biodels Scientific Advisory Board
11. Evotec AG: Fiscal Year 2007 Results Presentation on March 28, 2008 Live on the Internet
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... 2017 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: ... the three months ended December 31, 2016. ... and diagnostics company that develops and commercializes proprietary technologies and ... ... the commercial milestones achieved in fiscal 2016," said Andrew ...
(Date:2/21/2017)... ... 21, 2017 , ... Genedata, a leading provider of advanced ... establishment of Genedata Limited as a new subsidiary in the United Kingdom. The ... science informatics. Creating the UK subsidiary reinforces Genedata’s commitment to collaborate closely with ...
(Date:2/21/2017)... IL (PRWEB) , ... February ... ... of the Life -Sciences division, Treximo will pair its $200M operational capacity ... results-based consulting and project management in areas affecting quality and operational management. ...
(Date:2/21/2017)... VANCOUVER, British Columbia , Feb. 21, 2017 /PRNewswire/ ... that apatorsen results from two randomized Phase 2 clinical trials ... 2017 Genitourinary Cancers Symposium, held February 16 th - 18 ... from trials in bladder and prostate cancers demonstrated apatorsen was ... standard-of-care treatments. ...
Breaking Biology Technology:
(Date:2/3/2017)...  Texas Biomedical Research Institute announced that its Board of ... as the Institute,s new President and CEO. Dr. Schlesinger will ... He is currently the Chair of the Department of Microbial ... Interface Biology at Ohio State University. "We are ... CEO of Texas Biomed," said Dr. James O. Rubin ...
(Date:2/2/2017)... 2017   TapImmune, Inc. (NASDAQ: ... in the development of innovative peptide and gene-based ... and metastatic disease, announced today it has successfully ... a second clinical lot of TPIV 200, the ... The manufactured vaccine product will be used to ...
(Date:2/2/2017)... , Feb. 1, 2017  Central to ... and meaningful advances worldwide, The Japan Prize Foundation ... Prize, who have pushed the envelope in their ... and Communication. Three scientists are being recognized with ... achievements that not only contribute to the advancement ...
Breaking Biology News(10 mins):